Tier 2 — strong

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

Lin Yi, Andrea B Maier, Rongsheng Tao, Zhigang Lin, Aditi Vaidya, Sohal Pendse, Sornaraja Thasma, Niranjan Andhalkar, Ganesh Avhad, Vidyadhar Kumbhar
GeroScience 2023 45(1):29-43

Bibliography

PubMed
PMID 36482258
PubMed Central
PMC9735188
DOI
10.1007/s11357-022-00705-1
Funding
The trial was funded by Aba Chemicals and Abinopharm, companies associated with the investigational NMN product.
Competing interests
Lin Yi was affiliated with Abinopharm, and Rongsheng Tao and Zhigang Lin were affiliated with Aba Chemicals; the remaining authors reported no relevant conflict in the published paper.

Study snapshot

DesignRandomized, multicenter, double-blind, placebo-controlled, parallel-group dose-ranging trial.
ModelGenerally healthy adults aged 40–65 years.
Samplen=80; 20 each to placebo, 300 mg, 600 mg or 900 mg NMN.
Interventionβ-NMN 300, 600 or 900 mg once daily versus placebo.
Duration60 days.
EndpointsBlood NAD concentration; Safety and tolerability; Six-minute walk test; Blood biological-age estimate; HOMA-IR; SF-36

What the study showed, in plain terms

This dose-ranging trial randomized 80 middle-aged adults to placebo or 300, 600 or 900 mg/day NMN for 60 days. Blood NAD+ rose across NMN groups, with a dose-related pattern.

Six-minute-walk performance and some patient-reported health measures improved in parts of the NMN groups, while the biological-age and metabolic endpoints were exploratory. The study is useful for dose-response and short-term safety but was funded by companies associated with the product.

Key findings

  • Blood NAD+ increased after NMN supplementation, with greater increases at higher doses.
  • The study reported improvements in six-minute-walk distance in NMN groups versus baseline/control patterns.
  • No major short-term safety signal emerged across 300–900 mg/day.
  • Subsequent papers used this same trial dataset for post-hoc personalized-response and laboratory-association analyses.

What this study can and cannot tell us

The trial lasted only 60 days and included multiple secondary and exploratory outcomes. It was industry funded, and later post-hoc papers should not be counted as independent trials. Clinical-event outcomes were not assessed.

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology